<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25628211</article-id>
      <article-id pub-id-type="pmc">4879926</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082014AI2901</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082014AI2901</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Learning by Images</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cornea verticillata caused by Fabry diseaseC&#xF3;rnea verticilata por doen&#xE7;a de Fabry</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Ana Luiza Fontes de Azevedo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roisman</surname>
            <given-names>Victor</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Thiago Gon&#xE7;alves dos Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Hospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brazil.</aff>
      <aff id="aff2"><label>2</label>Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <aff id="aff3"><label>3</label>Universidade Federal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <author-notes>
        <corresp>Corresponding author: Ana Luiza Fontes de Azevedo Costa &#x2212; Rua Sacadura Cabral, 178 &#x2212; Zip code: 20221-903 &#x2212; Rio de Janeiro, RJ, Brazil &#x2212; E-mail: <email>luizafacosta@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Oct-Dec</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Oct-Dec</season>
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <issue>4</issue>
      <fpage>527</fpage>
      <lpage>528</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This work is licensed under a Creative Commons Attribution 4.0 International License.</license-p>
        </license>
      </permissions>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="4"/>
        <page-count count="2"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Biomicroscopy showing the corneal verticillata</title></caption><graphic xlink:href="1679-4508-eins-12-4-0527-gf01"/></fig>
</p>
    <p>A 33-year-old woman who works as a yoga teacher and lived in the city of Rio de Janeiro (RJ) - Brazil, sought ophthalmologic care at a routine examination. She did not report comorbidities and previous or regular use of medicines of any type. At examination the patient had good corrected visual acuity of 20/20 in both eyes. Biomicroscopy showed bilateral corneal verticillata, and in the rest of examination no other abnormalities were seen.</p>
    <p>Fabry disease is hereditary and X-chromosome linked. This disease is caused by deficiency of the enzyme &#x3B1;-galactosidase A that leads to progressive accumulation of lipid substances in the interior of the endothelium and smooth muscles of blood vessels so that affecting several organs.<sup>(<xref rid="B1" ref-type="bibr">1</xref>) </sup>Men are more affected by Fabry disease because they had the X chromosome to codify the enzyme &#x3B1;-galactosidase. Heterozygote women are commonly the carriers of the Fabry gene (GLA gene, the only gene identified so far), which present a random activity of the enzyme &#x3B1;-galactosidase A that turns its dosage less reliable for the diagnosis. The genetic molecular test is the most reliable diagnostic method for Fabry in female carrier.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
    <p>Angiokeratoma, acroparesthesia, hypertrophic cardiomyopathy, anhidrosis and corneal verticillata are common features of Fabry disease. The disease&#x2019;s clinical course is heterogeneous and variable especially in women.<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>) </sup>
</p>
    <p>Corneal verticillata was the most found ophthalmology change in men an women with Fabry disease. It presents an incidence of 76.9% in men and 73.1% in women and was describe almost as pathognomonic.<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup> Initial lesion observed in cornea is diffuse subepithelial layer opacity that progressively adopt a verticillata appearance.<sup>(<xref rid="B1" ref-type="bibr">1</xref>) </sup>This appearance could be an isolated finding without other ocular abnormalities.<sup>(<xref rid="B2" ref-type="bibr">2</xref>) </sup>Overall, there is no impair in vision associated with this corneal alteration.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
    <p>The Fabry disease along with amiodarone therapy is the most common cause of this form of corneal opacity, and the simple history assessment of medication used by the patient helps to clarify the cause.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
    <p>The patient blood sample was sent to a Germany laboratory for molecular genetic test to confirm the diagnosis of Fabry disease. Our patient was probably heterozygote for Fabry disease because, up to the time of examination, she did not have any symptom of the disease expected the corneal alteration. However, in this case, the ophthalmologic investigation was essential to establish the diagnosis and give the patient the opportunity to understand risks and care needed to all sufferers of this rare condition.</p>
  </body>
  <back>
    <ref-list>
      <title>REFER&#xCA;NCIAS</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Mehta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <source>Fabry Disease</source>
          <year>2002</year>
          <month>8</month>
          <day>05</day>
          <date-in-citation content-type="access-date">[cited 2013 Oct 17]</date-in-citation>
          <person-group person-group-type="editor">
            <name>
              <surname>Pagon</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Adam</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Bird</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Dolan</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Fong</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <publisher-name>GeneReviews&#x2122;</publisher-name>
          <comment>Internet</comment>
          <publisher-loc>Seattle (WA)</publisher-loc>
          <publisher-name>University of Washington</publisher-name>
          <publisher-loc>Seattle</publisher-loc>
          <season>-</season>
          <comment>Available from<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK1292/">http://www.ncbi.nlm.nih.gov/books/NBK1292/</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sodi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ioannidis</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Davey</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pitz</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Ocular manifestations of Fabry&#x2019;s disease: data from the Fabry Outcome Survey</article-title>
          <source>Br J Ophthalmol</source>
          <year>2007</year>
          <volume>91</volume>
          <issue>2</issue>
          <fpage>210</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="pmid">16973664</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoffmann</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mayatepek</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Fabry disease-often seen, rarely diagnosed</article-title>
          <source>Dtsch Arztebl Int</source>
          <year>2009</year>
          <volume>106</volume>
          <issue>26</issue>
          <fpage>440</fpage>
          <lpage>447</lpage>
          <pub-id pub-id-type="pmid">19623315</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kono</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Podskarbi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lanzl</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Oligosymptomatic cornea verticillata in a heterozygote for Fabry disease: a novel mutation in the alpha-galactosidase gene</article-title>
          <source>Cornea</source>
          <year>2003</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>175</fpage>
          <lpage>177</lpage>
          <pub-id pub-id-type="pmid">12605057</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="TRen" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Aprendendo Por Imagens</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>C&#xF3;rnea verticilata por doen&#xE7;a de Fabry</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Ana Luiza Fontes de Azevedo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roisman</surname>
            <given-names>Victor</given-names>
          </name>
          <xref ref-type="aff" rid="aff2002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Thiago Gon&#xE7;alves dos Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff3002">
<sup>3</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1002"><label>1</label>Hospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brasil.</aff>
      <aff id="aff2002"><label>2</label>Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <aff id="aff3002"><label>3</label>Universidade Federal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <author-notes>
        <corresp> Autor correspondente: Ana Luiza Fontes de Azevedo Costa &#x2212; Rua Sacadura Cabral, 178 &#x2212; CEP: 20221-903 &#x2212; Rio de Janeiro, RJ, Brasil &#x2212; E-mail: <email>luizafacosta@hotmail.com</email></corresp>
      </author-notes>
    </front-stub>
    <body>
      <p>
<fig id="f1002" orientation="portrait" position="float"><label>Figura 1</label><caption><title>C&#xF3;rnea verticilata observada &#xE0; biomicroscopia</title></caption><graphic xlink:href="1679-4508-eins-12-4-0527-gf01-pt"/></fig>
</p>
      <p>Paciente do g&#xEA;nero feminino, 33 anos, professora de ioga, natural e residente da cidade do Rio de Janeiro (RJ), procurou atendimento oftalmol&#xF3;gico para exame de rotina. Negava comorbidades bem como uso regular pr&#xE9;vio ou atual de qualquer medica&#xE7;&#xE3;o. Apresentava melhor acuidade visual corrigida de 20/20 em ambos os olhos. &#xC0; biomicroscopia, observava-se c&#xF3;rnea verticilata bilateral, sem outras altera&#xE7;&#xF5;es no restante do exame.</p>
      <p>A doen&#xE7;a de Fabry &#xE9; heredit&#xE1;ria e est&#xE1; ligada ao cromossomo X. Consiste na defici&#xEA;ncia da enzima alfa-galactosidase A, que leva ao ac&#xFA;mulo progressivo de subst&#xE2;ncias lip&#xED;dicas no interior do endot&#xE9;lio e m&#xFA;sculos lisos de vasos sangu&#xED;neos comprometendo, assim, v&#xE1;rios &#xF3;rg&#xE3;os.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup> Acomete mais comumente homens, que s&#xF3; possuem um cromossomo X para codificar a enzima alfa-galactosidase. Mulheres heterozigotas s&#xE3;o normalmente carreadoras do gene da doen&#xE7;a de Fabry (GLA, at&#xE9; ent&#xE3;o o &#xFA;nico gene identificado), possuindo atividade variada da enzima alfa-galactosidase A, o que torna sua dosagem pouco confi&#xE1;vel para o diagn&#xF3;stico nesses casos. O teste molecular gen&#xE9;tico &#xE9; o mais confi&#xE1;vel para o diagn&#xF3;stico de Fabry em mulheres carreadoras.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>
</p>
      <p>Angioceratoma, acroparestesias, cardiomiopatia hipertr&#xF3;fica, anidrose e c&#xF3;rnea verticilata s&#xE3;o as t&#xED;picas manifesta&#xE7;&#xF5;es da doen&#xE7;a de Fabry. Seu curso cl&#xED;nico &#xE9; heterog&#xEA;neo e variado, especialmente em mulheres.<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
      <p>A c&#xF3;rnea verticilata foi a altera&#xE7;&#xE3;o oftalmol&#xF3;gica mais encontrada em homens e mulheres com Fabry, com incid&#xEA;ncia de 76,9% nas mulheres e de 73,1% nos homens, sendo descrita como quase patognom&#xF4;nica.<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup> A les&#xE3;o inicial observada na c&#xF3;rnea &#xE9; uma opacidade difusa na camada supepitelial que, progressivamente, adota o aspecto de verticilata.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup> Pode ser um achado isolado sem outras anormalidades oculares.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup> Normalmente, n&#xE3;o h&#xE1; baixa visual associada a essa altera&#xE7;&#xE3;o.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
      <p>Juntamente do tratamento com amiodarona, a doen&#xE7;a de Fabry &#xE9; a causa mais comum dessa forma de opacidade corneana, e a simples avalia&#xE7;&#xE3;o do hist&#xF3;rico de uso de medica&#xE7;&#xF5;es ajuda a esclarecer a causa.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
      <p>Diante da suspeita, a amostra sangu&#xED;nea da paciente foi enviada a um laborat&#xF3;rio alem&#xE3;o, para teste molecular gen&#xE9;tico, para a confirma&#xE7;&#xE3;o do diagn&#xF3;stico. Podemos inferir que a paciente provavelmente &#xE9; heterozigota para a doen&#xE7;a de Fabry, j&#xE1; que, at&#xE9; ent&#xE3;o, n&#xE3;o apresentou sintoma algum da doen&#xE7;a, sendo apenas observada a altera&#xE7;&#xE3;o corneana. Apesar disso, a investiga&#xE7;&#xE3;o oftalmol&#xF3;gica, neste caso, foi essencial para que o diagn&#xF3;stico fosse estabelecido e que a paciente pudesse estar ciente dos riscos e cuidados necess&#xE1;rios a todos os portadores dessa condi&#xE7;&#xE3;o rara.</p>
    </body>
  </sub-article>
</article>
</pmc-articleset>
